Kevin Sharer

(Newser) - Amgen didn’t do terribly well under CEO Kevin Sharer last year—it eliminated some 2,700 jobs and its stock fell 3%. Yet Sharer pocketed a 37% raise, bringing his compensation to $21 million. Why? Because the board decided he should be paid “closer to the 75th percentile...

(Newser) - Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune...